Please login to the form below

Not currently logged in
Email:
Password:

ozanimod

This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.

BMS shares positive long-term data for Zeposia in relapsing multiple sclerosis

BMS shares positive long-term data for Zeposia in relapsing multiple sclerosis

Bristol Myers Squibb (BMS) has shared new long-term data from a study evaluating Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis (RMS).

Latest news

More from news
Approximately 5 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    The FDA accepted the filing for Ozanimod in June 2019 with a target PDUFA date of 25 March 2020. ... As with ozanimod, if OMB-157 is approved it will find a very crowded multiple sclerosis market with some very notable competitors, particularly in the

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    treatment ozanimod and myelodysplastic syndromes/beta thalassaemia candidate luspatercept – to deliver on their potential.

  • Pharma deals in July 2015 Pharma deals in July 2015

    Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Redbow Consulting Group

Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
...
New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...